Nutriband Engages with FDA to Advance AVERSA™ FENTANYL Development
Nutriband has recently held a pivotal meeting with the US FDA to discuss critical feedback regarding the Chemistry, Manufacturing, and Controls (CMC) plans for its innovative AVERSA™ FENTANYL product, a transdermal system designed to deter abuse.
Meeting Outcomes and Insights
The company received the finalized minutes from its virtual meeting with the FDA, which took place on September 18, 2025. This engagement was instrumental as Nutriband works towards filing an Investigational New Drug Application (IND) for a clinical study focused on Human Abuse Potential (HAP).
Feedback and Guidance from the FDA
During the meeting, crucial insights were shared regarding the regulatory pathway, confirming that the AVERSA™ product falls under the 505(b)(2) New Drug Application (NDA) framework. The FDA provided essential advice on several aspects:
- Clarifications on the reference listed drug upon which their application would rely.
- Expectations for the manufacturing process and registration batch plan.
- Guidance regarding product specifications and stability testing plans.
- Recommendations for in vitro studies to characterize the product's abuse-deterrent properties.
Nutriband's Commitment to Safety
The Division acknowledged the pressing issue of fentanyl patches, including cases of abuse and accidental exposure, particularly among vulnerable populations such as children. The FDA expressed their willingness to support Nutriband throughout the development process, ensuring that necessary precautions are in place.
Nutriband stands on the brink of potentially offering the world's first approved abuse-deterrent fentanyl patch, a significant breakthrough in ensuring patient safety while effectively managing pain.
Company Leadership's Vision
“We are thankful for the opportunity to discuss the CMC aspects of our product with the Agency,” said Alan Smith, Ph.D., Chief Operating Officer of Nutriband. “The constructive feedback we have received will be invaluable as we move forward with our IND filing process.”
Collaborative Efforts with Kindeva
Nutriband is partnering with Kindeva, combining their expertise in drug delivery systems with Nutriband’s innovative AVERSA™ technology. This collaboration aims to maximize the efficacy and safety of the AVERSA™ FENTANYL patch.
AVERSA™ Technology Overview
The AVERSA™ technology incorporates aversive agents into transdermal systems, significantly minimizing the risk of abuse, diversion, misuse, and accidental exposure. This development is anticipated to enhance the safety profile of drugs known for their abuse potential, ensuring that they remain accessible for patients who truly rely on them.
Market Potential and Global Outlook
The AVERSA™ FENTANYL product is poised for substantial financial success, with projected annual sales ranging from $80 million to $200 million. While the initial focus remains on the US market, Nutriband recognizes the global need for improved pain management solutions and plans to introduce the product in major markets worldwide.
Moreover, Nutriband's AVERSA™ technology is supported by a comprehensive intellectual property portfolio, with patents granted in numerous countries, including the United States, Europe, and Asia, safeguarding their innovations as they prepare for market entry.
Frequently Asked Questions
What is the purpose of the meeting with the FDA?
The meeting aimed to discuss feedback on the Chemistry, Manufacturing, and Controls plans for Nutriband's AVERSA™ FENTANYL product and to guide its further development.
What are the expected outcomes from AVERSA™ FENTANYL?
Nutriband anticipates that AVERSA™ FENTANYL could become the first approved abuse-deterrent fentanyl patch worldwide, addressing significant safety concerns.
How does AVERSA™ technology work?
The technology embeds aversive agents within transdermal patches to reduce the potential for abuse and ensure medications remain safe for those in need.
What market potential does Nutriband see for AVERSA™ FENTANYL?
Nutriband estimates potential peak annual sales of AVERSA™ FENTANYL to be between $80 million and $200 million, with plans for global expansion.
Who is Nutriband collaborating with for this product?
Nutriband is partnering with Kindeva to leverage their expertise in drug delivery alongside Nutriband's innovative technologies for developing AVERSA™ FENTANYL.
